Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Will the Angiotensin Receptor Blockers (ARBs) Market Evolve in Terms of Growth and Size by 2029?

The market size for Angiotensin Receptor Blockers (ARBS) has seen consistent growth in recent years. From $8.51 billion in 2024, it is predicted to expand to $8.78 billion in 2025, reflecting a Compound Annual Growth Rate (CAGR) of 3.1%. Factors such as the increasing prevalence of hypertension, the proven clinical efficacy of ARBs, burden of cardiovascular disease, renal protection, clinical guidelines, the preference for ARBs as a frontline treatment, and their cost-effectiveness have all contributed to growth during the historic period.

The market size for angiotensin receptor blockers (arbs) is anticipated to see a consistent surge in growth over the next few years. This market is projected to expand to $10.52 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 4.6%. The expansion during the forecasted period can be credited to factors such as precision medicine methodologies, emphasis on combination therapies, worldwide market expansion, strategies based on biomarker treatment, governmental initiatives, and heightened awareness about hypertension. The forecast period will also see major trends like the adoption of telemedicine, investment in research and development, competition from generic drugs and patent terminations, digital health tools to enhance medication adherence, and competition from biosimilars.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8943&type=smp

What factors are expected to fuel Angiotensin Receptor Blockers (ARBs) market growth in the coming years?

The growth of the angiotensin receptor blockers market is anticipated to be boosted by the rising prevalence of cardiovascular diseases. Cardiovascular disease (CVD), a condition that impacts the heart or blood vessels, often correlates with the formation of fatty deposits within the arteries (atherosclerosis) and a heightened risk of blood clots. Angiotensin receptor blockers, which lower blood pressure and enhance the heart’s ability to circulate blood by aiding in the relaxation of veins and arteries, can help reduce the risk of cardiovascular disease. As an example, the American College of Cardiology, a professional medical organization in the U.S., projected in August 2022 that the rates of cardiovascular risk factors and illnesses would see a significant increase in the United States by 2060. Consequently, the escalating prevalence of cardiovascular diseases is stimulating the angiotensin receptor blockers market’s growth.

What Are The Key Findings From The Segmentation Analysis Of The Angiotensin Receptor Blockers (ARBs) Market?

The angiotensin receptor blockers (arbs) market covered in this report is segmented –

1) By Product: Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, Olmesartan

2) By Application: Hypertension, Cardiovascular Diseases, Kidney Diseases, Other Applications

3) By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers

Subsegments:

1) By Valsartan: Tablets, Capsules, Injectable Forms

2) By Telmisartan: Tablets, Capsules

3) By Losartan: Tablets, Oral Solution

4) By Irbesartan: Tablets, Oral Solution

5) By Azilsartan: Tablets

6) By Olmesartan: Tablets, Oral Suspension

Which Trends Are Expected To Shape The Future Of The Angiotensin Receptor Blockers (ARBs) Market?

Leading firms in the angiotensin receptor blocker market are innovating with sophisticated products such as angiotensin receptor neprilysin inhibitors to augment treatment alternatives and boost patient outcomes for cardiovascular diseases. These inhibitors, known as ARNIs, are a category of drugs applied in heart failure treatment. For instance, Glenmark Pharmaceuticals, an Indian company, introduced sacubitril + valsartan tablets in January 2023, a specialized treatment for heart failure, particularly heart failure with reduced ejection fraction (HFrEF). This combination is classified under ARNI medications. Sacubitril amplifies the natriuretic peptide (NP) system to relieve fluid overload and foster blood vessel expansion, while valsartan restricts the renin-angiotensin system (RAS) to reduce blood pressure and minimize the workload of the heart. Together, both components enhance heart failure symptoms, lower the risk of cardiovascular death, and shrink the likelihood of heart failure-related hospitalizations. They are sold under the brand name Sacu V.

What Are The Most Active Companies In The Angiotensin Receptor Blockers (ARBs) Market Today?

Major companies operating in the angiotensin receptor blockers (ARBs) market include Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Lupin Limited, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific, Sanofi, Johnson & Johnson, Eli Lilly, Bayer AG, Abbvie Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Zydus Cadila, Glenmark Pharmaceuticals Ltd., Cipla Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zhejiang Huahai Pharmaceutical Co. Ltd., Boehringer Ingelheim Ltd., Astellas Pharma

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/angiotensin-receptor-blockers-arbs-global-market-report

Which Regional Markets Are Attracting The Most Investment In Angiotensin Receptor Blockers (ARBs)?

North America was the largest region in the angiotensin receptor blockers (ARBs) market share in 2024. The regions covered in the angiotensin receptor blockers (ARBs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=8943&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model